Abstract
Lobenzarit (CCA) is an antiarthritic agent synthesized by Chugai Pharmaceutical Co., Ltd, Tokyo, Japan. It was selected for investigation as a result of immunopharmacologic screening tests of various immunologic responses induced by the interactions of immunocompetent cells. Extensive studies of lobenzarit have revealed significant effects on the immune system. In animals the compound has proven to be effective in preventing and reducing the severity of glomerulonephritis in NZB/NZW F1 hybrid mice, which are immunologically predisposed to the disease. It also inhibits the development of spontaneous arthritis and nephritis in MRL/Mp-1pr/lpr (MRL/l) mice.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abe C, Shiokawa Y, Ohishi T, Hata S, Takagaki Y (1981) The effect of N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt (CCA) on spontaneous autoimmune disorders in MRL/1 mice. Ryumachi [Suppl] 21: 165
Aritomi H (1985) Radiographic evaluation of the effect of remission inducing drugs in rheumatoid arthritis. In: Nobunaga T (ed) 3rd symposium on clinical trial of drugs–assessments of efficacy for immunomodulators. Nagai-shoten, Osaka, p 103–104
Hata S, Nakano T, Niki R, Takagaki Y, Sakai S (1980) Effect of CCA on the experimental amyloidosis induced by lipopolysaccharide in C3H/He mice. Jpn J Inflammation 1: 145
Itoh K (1983) Mechanism of suppression of chronic inflammation by CCA. I. Effect of CCA on activated macrophage. 4th Conference of the Japanese Society of Inflammation, Tokyo
Itoh K, Kurane I, Saito F, Kawakami K, Kosaka S, Kumagai K (1983) The IFN-inducing ability and immunoregulatory action of CCA. Clin Immunol 15: 242
Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and re- lated conditions by standard reference films. Acta Radiol [Diagn] (Stockh) 18: 481
Maeda A (1985) A long-term clinical trial of CCA. In: Nobunaga T (ed) 3rd symposium on clinical trials of drugs — assessments of efficacy for immunomodulators. Nagaishoten, Osaka, p 78–79
Nakano T, Yamashita Y, Ohsugi Y, Sugawara Y, Hata S, Takagaki Y (1983) The effect of CCA (lobenzarit disodium) on the suppressor T cell function and the production of autoantibodies in NZB x NZW F1 mice. Immunopharmacology 5: 293
Nakazawa T, Abe C, Shiokawa Y, Kamijo K (1984) Carboxyphenyl chloroanthranilic acid ( CCA) in the modulation of immune response in mice. Int J Tissue React 6: 23
Ogawa H, Tsunematsu T (1982) Effects of immunomodulating agents on human suppressor T lymphocytes. Allergy 31: 207
Ohsugi Y, Nakano T, Hata S, Matsuno T, Nishii Y, Takagaki Y (1977 a) Disodium N-(2carboxyphenyl)-4-chloroanthranilate: enhancement of immune response in mice. Chem Pharm Bull (Tokyo) 25: 2143
Ohsugi Y, Hata S, Tanemura M, Nakano T, Matsuno T, Takagaki Y, Nishii Y, Shindo M (1977 b) N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt: a novel anti-arthritic agents without anti-inflammatory and immunosuppressive activities. J Pharm Pharmacol 29: 636
Ohsugi Y, Nakano T, Hata S, Niki R, Matsuno T, Nishii Y, Takagaki Y (1978) N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt: prevention of autoimmune kidney disease in NZB/NZW F1 hybrid mice. J Pharm Pharmacol 30: 126
Ohsugi Y, Nakano T, Hata S (1983) A novel anti-arthritic agent, CCA (lobenzarit sodium); and the role of thymus-derived lymphocytes in the inhibition of rat adjuvant arthritis. Immunopharmacology 6: 15
Ohsugi Y, Nakano T, Ueno K, Fukui H, Niki R, Sugawara Y, Hata S ( 1985 a) An immunopharmacological profile of lobenzarit disodium ( CCA), a new immunomodulating anti-rheumatic drug. Int J Immunother 1: 85
Ohsugi Y, Nakano T, Ueno K, Sugawara Y ( 1985 b) CCA pharmacology: preclinical evaluation for effects on experimental arthritis and immunomodulative effects. In: Nobunaga T (ed) 3rd symposium on clinical trials of drugs — assessments of efficacy for immunomodulators. Nagai-shoten, Osaka, p 67–69
Shiokawa Y, Abe C (1985) Immunotherapy of connective tissue disease. Proceedings of the 3rd international conference on immunopharmacology, Florence, Italy, 6–9 May 1985. In: Chedid L (ed) Advances in immunopharmacology, p 75–81
Shiokawa Y, Horiuchi Y, Mizushima Y, Kageyama T, Shichikawa K, Ofuji T, Honma M et al. (1984) A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, on rheumatoid arthritis. J Rheumatol 11: 615
Sonozaki T, Mitsui H (1984) T cell abnormality in rheumatoid arthritis and effect of immunopotentiator. Ryumachi 24: 3
Tanemura M, Kaiho S, Mizuno K, Nogaki K, Hata S, Takagaki Y (1984) Effect of an immunomodulator agent CCA on inflammatory response in various animal models. Jpn J Inflammation 4: 239
Watanabe H, Yanagawa A, Shoji Y, Mizushima Y (1983) A study of the immunomodulating effect of CCA. Jpn J Inflammation 3: 156
Yamamoto I, Ohmori Y, Sasano M (1982) CCA: an immunopharmacological profile in vivo and in vitro. Drug Exp Clin Res 8: 5
Yamamoto I, Ohmori H, Sasano M (1983) Effect of N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt ( CCA) on the induction of helper and suppressor T cells in vitro and in vivo. Jpn J Pharmacol 33: 859
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shiokawa, Y. (1988). Lobenzarit (CCA). In: Bray, M.A., Morley, J. (eds) The Pharmacology of Lymphocytes. Handbook of Experimental Pharmacology, vol 85. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73217-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-73217-1_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73219-5
Online ISBN: 978-3-642-73217-1
eBook Packages: Springer Book Archive